Anaconda Pharma Report issue

For profit Phase 2
Founded: Villejuf France (2003)
Status: Acquired by Aviragen Therapeutics (2015) → now Vaxart (2017)

Organization Overview

First Clinical Trial
2012
NCT01532102
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

ap611074 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Condylomata Acuminata (Phase 2)

Papillomavirus Infections (Phase 2)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1